NASDAQ:ZVRA Zevra Therapeutics (ZVRA) Stock Forecast, Price & News $5.40 -0.03 (-0.55%) (As of 09:02 AM ET) Add Compare Share Share Today's Range$5.40▼$5.4050-Day Range$4.23▼$6.2952-Week Range$4.03▼$6.92Volume7,730 shsAverage Volume231,863 shsMarket Capitalization$186.52 millionP/E RatioN/ADividend YieldN/APrice Target$12.00 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesHeadlinesOptions ChainSEC FilingsShort InterestSocial Media Zevra Therapeutics MarketRank™ ForecastAnalyst RatingBuy3.00 Rating ScoreUpside/Downside121.0% Upside$12.00 Price TargetShort InterestBearish6.39% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.06Based on 2 Articles This WeekInsider TradingAcquiring Shares$178,055 Bought Last QuarterProj. Earnings GrowthGrowingFrom ($1.47) to ($0.79) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.79 out of 5 starsMedical Sector727th out of 982 stocksPharmaceutical Preparations Industry354th out of 474 stocks 3.5 Analyst's Opinion Consensus RatingZevra Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $12.00, Zevra Therapeutics has a forecasted upside of 121.0% from its current price of $5.43.Amount of Analyst CoverageZevra Therapeutics has only been the subject of 1 research reports in the past 90 days. Previous Next 1.0 Short Interest Percentage of Shares Shorted6.39% of the float of Zevra Therapeutics has been sold short.Short Interest Ratio / Days to CoverZevra Therapeutics has a short interest ratio ("days to cover") of 7.7.Change versus previous month Previous Next 0.0 Dividend Strength Dividend YieldZevra Therapeutics does not currently pay a dividend.Dividend GrowthZevra Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for ZVRA. Previous Next 1.7 News and Social Media Coverage News SentimentZevra Therapeutics has a news sentiment score of 0.06. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.52 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Zevra Therapeutics this week, compared to 3 articles on an average week.Search Interest8 people have searched for ZVRA on MarketBeat in the last 30 days. This is an increase of 167% compared to the previous 30 days.MarketBeat FollowsOnly 2 people have added Zevra Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Zevra Therapeutics insiders have bought more of their company's stock than they have sold. Specifically, they have bought $178,055.00 in company stock and sold $0.00 in company stock.Percentage Held by InsidersOnly 1.10% of the stock of Zevra Therapeutics is held by insiders.Percentage Held by InstitutionsOnly 19.39% of the stock of Zevra Therapeutics is held by institutions. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Zevra Therapeutics are expected to grow in the coming year, from ($1.47) to ($0.79) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Zevra Therapeutics is -3.64, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Zevra Therapeutics is -3.64, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioZevra Therapeutics has a P/B Ratio of 2.18. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Zevra Therapeutics (NASDAQ:ZVRA) StockZevra Therapeutics, Inc. is a clinical-stage specialty pharmaceutical company, which engages in the discovery and development of proprietary prodrugs. It focuses on the treatment of serious medical conditions such as attention deficit hyperactivity disorder, pain, and other central nervous system disorders through its platform technology known as Ligand Activated Therapy. The company was founded by Christal M. M. Mickle and Travis C. Mickle on October 30, 2006 and is headquartered in Celebration, FL.Read More Receive ZVRA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Zevra Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address ZVRA Stock News HeadlinesJune 3, 2023 | finance.yahoo.comZevra Therapeutics Presents Design of Phase 2 Clinical Trial Investigating KP1077 for the Treatment of Idiopathic Hypersomnia (IH) at Beyond Sleepy 2023May 21, 2023 | americanbankingnews.comInsider Buying: Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Director Buys 10,000 Shares of StockJune 7, 2023 | Edge On The Street (Ad)The $193 Billion US-China War You Don't Know AboutThey're fighting for control of lithium – a key ingredient in EVs and clean energy technology. It's arguably the most important commodity of the 21st century. China owns 80% of global supply. But the US plans to grab a massive slice of the lithium market, which is forecasted to quadruple to $193 billion by 2028, according to Fortune Business Insights.May 20, 2023 | americanbankingnews.comR. Laduane Clifton Purchases 2,740 Shares of Zevra Therapeutics, Inc. (NASDAQ:ZVRA) StockMay 17, 2023 | americanbankingnews.comZevra Therapeutics (NASDAQ:ZVRA) Releases Earnings Results, Misses Expectations By $0.08 EPSMay 16, 2023 | finance.yahoo.comQ1 2023 Zevra Therapeutics Inc Earnings CallMay 15, 2023 | washingtonpost.comZevra Therapeutics: Q1 Earnings SnapshotMay 15, 2023 | finance.yahoo.comZevra Therapeutics (ZVRA) Reports Q1 Loss, Tops Revenue EstimatesJune 7, 2023 | Edge On The Street (Ad)The $193 Billion US-China War You Don't Know AboutThey're fighting for control of lithium – a key ingredient in EVs and clean energy technology. It's arguably the most important commodity of the 21st century. China owns 80% of global supply. But the US plans to grab a massive slice of the lithium market, which is forecasted to quadruple to $193 billion by 2028, according to Fortune Business Insights.May 15, 2023 | finance.yahoo.comZevra Therapeutics Reports Corporate Updates and First Quarter 2023 Financial ResultsMay 12, 2023 | msn.comA Preview Of Zevra Therapeutics's EarningsMay 10, 2023 | finance.yahoo.comZevra Therapeutics will Participate in RBC Capital Markets Global Healthcare Conference on May 16, 2023May 9, 2023 | finance.yahoo.comZevra Therapeutics to Report First Quarter 2023 Results on May 15, 2023May 8, 2023 | msn.comZevra Therapeutics CEO resigns, Tamara Favorito appointed as Chair of the BoardMay 8, 2023 | finance.yahoo.comZevra Announces Board of Directors and Leadership ChangesMay 4, 2023 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Zevra Therapeutics (ZVRA) and Morphosys Ag (MOR)May 3, 2023 | finance.yahoo.comZevra Therapeutics Announces FDA Acceptance of IND Application for KP1077 in NarcolepsyApril 21, 2023 | americanbankingnews.comHead-To-Head Review: Zevra Therapeutics (NASDAQ:ZVRA) and ERBA Diagnostics (OTCMKTS:ERBA)April 18, 2023 | seekingalpha.comZVRA Zevra Therapeutics, Inc.April 17, 2023 | benzinga.comLeading Proxy Advisory Firms ISS and Glass Lewis Demonstrate Strong Support for Zevra's Transformation StrategyApril 17, 2023 | finance.yahoo.comLeading Proxy Advisory Firms ISS and Glass Lewis Demonstrate Strong Support for Zevra’s Transformation StrategyApril 17, 2023 | finance.yahoo.comWhy Investors Shouldn't Be Surprised By Zevra Therapeutics, Inc.'s (NASDAQ:ZVRA) 31% Share Price SurgeApril 11, 2023 | americanbankingnews.comZevra Therapeutics (ZVRA) versus Its Peers Head-To-Head ComparisonApril 6, 2023 | investing.comZevra Therapeutics Inc (ZVRA)April 4, 2023 | finance.yahoo.comZevra Therapeutics Announces Submission of IND for KP1077 in NarcolepsyApril 3, 2023 | americanbankingnews.comZevra Therapeutics (ZVRA) & Its Peers Head-To-Head SurveyMarch 30, 2023 | thestreet.comZevra Therapeutics Inc.See More Headlines ZVRA Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ZVRA Company Calendar Last Earnings5/15/2023Today6/07/2023Next Earnings (Estimated)8/10/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:ZVRA CUSIPN/A CIK1434647 Webwww.kempharm.com Phone(321) 939-3416Fax319-665-2577EmployeesN/AYear FoundedN/APrice Target and Rating Average Stock Price Forecast$12.00 High Stock Price Forecast$12.00 Low Stock Price Forecast$12.00 Forecasted Upside/Downside+121.0%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)($1.49) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-41,540,000.00 Net Margins-548.93% Pretax Margin-558.38% Return on Equity-38.58% Return on Assets-29.00% Debt Debt-to-Equity Ratio0.18 Current Ratio6.68 Quick Ratio6.68 Sales & Book Value Annual Sales$10.46 million Price / Sales17.93 Cash FlowN/A Price / Cash FlowN/A Book Value$2.49 per share Price / Book2.18Miscellaneous Outstanding Shares34,540,000Free Float34,160,000Market Cap$187.55 million OptionableOptionable Beta2.19 Key ExecutivesRichard W. PascoeChief Executive Officer & DirectorR. LaDuane CliftonChief Financial Officer, Secretary & TreasurerSven GuentherChief Scientific OfficerDaniel GalloSenior Vice President-Medical Affairs & AdvocacyTimothy J. SangiovanniVice President & ControllerKey CompetitorsInflaRxNASDAQ:IFRXImmutepNASDAQ:IMMPPDS BiotechnologyNASDAQ:PDSBKinnate BiopharmaNASDAQ:KNTEAC ImmuneNASDAQ:ACIUView All CompetitorsInsidersCorey Michael WattonBought 400 shares on 5/30/2023Total: $2,044.00 ($5.11/share)R. Laduane CliftonBought 2,740 shares on 5/18/2023Total: $13,563.00 ($4.95/share)John B BodeBought 10,000 shares on 5/18/2023Total: $50,400.00 ($5.04/share)Tamara A SeymourBought 519 shares on 3/17/2023Total: $2,501.58 ($4.82/share)Joshua SchaferBought 2,000 shares on 3/14/2023Total: $9,220.00 ($4.61/share)View All Insider Transactions ZVRA Stock - Frequently Asked Questions Should I buy or sell Zevra Therapeutics stock right now? 1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Zevra Therapeutics in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" ZVRA shares. View ZVRA analyst ratings or view top-rated stocks. What is Zevra Therapeutics' stock price forecast for 2023? 1 Wall Street research analysts have issued twelve-month target prices for Zevra Therapeutics' stock. Their ZVRA share price forecasts range from $12.00 to $12.00. On average, they anticipate the company's share price to reach $12.00 in the next twelve months. This suggests a possible upside of 121.0% from the stock's current price. View analysts price targets for ZVRA or view top-rated stocks among Wall Street analysts. How have ZVRA shares performed in 2023? Zevra Therapeutics' stock was trading at $5.39 at the start of the year. Since then, ZVRA shares have increased by 0.7% and is now trading at $5.43. View the best growth stocks for 2023 here. When is Zevra Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, August 10th 2023. View our ZVRA earnings forecast. How were Zevra Therapeutics' earnings last quarter? Zevra Therapeutics, Inc. (NASDAQ:ZVRA) issued its quarterly earnings data on Monday, May, 15th. The company reported ($0.34) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.26) by $0.08. The business had revenue of $2.88 million for the quarter, compared to analysts' expectations of $2.77 million. Zevra Therapeutics had a negative trailing twelve-month return on equity of 38.58% and a negative net margin of 548.93%. What ETF holds Zevra Therapeutics' stock ? iShares Neuroscience and Healthcare ETF holds 3,689 shares of ZVRA stock, representing 0.43% of its portfolio. What is Zevra Therapeutics' stock symbol? Zevra Therapeutics trades on the NASDAQ under the ticker symbol "ZVRA." How do I buy shares of Zevra Therapeutics? Shares of ZVRA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Zevra Therapeutics' stock price today? One share of ZVRA stock can currently be purchased for approximately $5.43. How much money does Zevra Therapeutics make? Zevra Therapeutics (NASDAQ:ZVRA) has a market capitalization of $187.55 million and generates $10.46 million in revenue each year. The company earns $-41,540,000.00 in net income (profit) each year or ($1.49) on an earnings per share basis. How can I contact Zevra Therapeutics? Zevra Therapeutics' mailing address is 1180 Celebration Boulevard Suite 103, Celebration FL, 34747. The official website for the company is www.kempharm.com. The company can be reached via phone at (321) 939-3416, via email at jrando@tiberend.com, or via fax at 319-665-2577. This page (NASDAQ:ZVRA) was last updated on 6/7/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Zevra Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.